An observational study in Meibomian Gland Dysfunction, sponsored by Wenzhou Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.
Sponsored by Wenzhou Medical University · Observational
Among 20 studies in Meibomian Gland Dysfunction with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Meibomian Gland Dysfunction · China.
Among the 20 studies in Meibomian Gland Dysfunction with a site in China, this one is the only one that started in 2016, is one of 6 observational ones, and was the 1st registered.
172 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.
Browse Meibomian Gland Dysfunction studies →4 of the 20 studies in Meibomian Gland Dysfunction with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Zhongnan Hospital · Sites in China
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stop at 75 or younger; 1 take children under 18; 1 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 65 across 25 observational studies indexed under Meibomian Gland Dysfunction.
Median enrollment 95 across the 14 interventional studies, 81 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
Wenzhou Medical University is the lead sponsor of 94 studies on the registry; 8 are open to participants now.
Wenzhou Medical University has 2 studies filed under Meibomian Gland Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies in Meibomian Gland Dysfunction with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07633938Zhongshan Ophthalmic Center, Sun Yat-sen UniversityThe Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial | 2027-07-01 |
Among the 20 studies in Meibomian Gland Dysfunction with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the correlation between the thickness of lipid layer and the meibomian gland dysfunction.
This study was consisted of patients who underwent the Meibomian Gland Dysfunction through the signs. The Office of Research Ethics,Eye Hospital of Wenzhou Medical University approved the study protocol, and all patients provided their informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lipid Layer Thickness
Time frame: up to 2 years
Atrophy of Meibomian Gland
Time frame: up to 2 years
The record gives a start of Jan 2016, a primary completion of Nov 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wenzhou Medical University